Galapagos NV ADR (GLPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos NV ADR (GLPG) has a cash flow conversion efficiency ratio of -0.013x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.67 Million) by net assets ($3.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galapagos NV ADR - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Galapagos NV ADR total liabilities for a breakdown of total debt and financial obligations.
Galapagos NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
0.100x |
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
-0.076x |
|
AUB GROUP LTD.
F:A5H
|
N/A |
|
Ivanhoe Electric Inc.
NYSE MKT:IE
|
-0.094x |
|
Tabcorp Holdings Ltd
AU:TAH
|
0.075x |
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
0.054x |
|
Intapp Inc
NASDAQ:INTA
|
0.028x |
|
Autek China Inc
SHE:300595
|
0.054x |
Annual Cash Flow Conversion Efficiency for Galapagos NV ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV ADR from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see Galapagos NV ADR market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.23 Billion | $-189.23 Million | -0.059x | +47.04% |
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -3.96% |
| 2021-12-31 | $2.64 Billion | $-503.83 Million | -0.191x | -19.10% |
| 2020-12-31 | $2.67 Billion | $-427.34 Million | -0.160x | -112.79% |
| 2019-12-31 | $2.88 Billion | $3.60 Billion | 1.251x | +1166.08% |
| 2018-12-31 | $1.21 Billion | $-142.47 Million | -0.117x | +19.24% |
| 2017-12-31 | $1.01 Billion | $-147.03 Million | -0.145x | -146.04% |
| 2016-12-31 | $758.70 Million | $239.40 Million | 0.316x | +200.51% |
| 2015-12-31 | $365.00 Million | $-114.59 Million | -0.314x | +14.35% |
| 2014-12-31 | $206.13 Million | $-75.56 Million | -0.367x | -11835.82% |
| 2013-12-31 | $167.14 Million | $522.00K | 0.003x | -99.42% |
| 2012-12-31 | $118.45 Million | $64.10 Million | 0.541x | +634.28% |
| 2011-12-31 | $118.38 Million | $-11.99 Million | -0.101x | +19.01% |
| 2010-12-31 | $148.51 Million | $-18.57 Million | -0.125x | -316.03% |
| 2009-12-31 | $108.88 Million | $6.30 Million | 0.058x | +159.47% |
| 2008-12-31 | $84.32 Million | $-8.21 Million | -0.097x | -2687.95% |
| 2007-12-31 | $98.63 Million | $371.00K | 0.004x | +104.43% |
| 2006-12-31 | $109.54 Million | $-9.31 Million | -0.085x | -33.68% |
| 2005-12-31 | $61.14 Million | $-3.89 Million | -0.064x | +75.68% |
| 2004-12-31 | $10.37 Million | $-2.71 Million | -0.261x | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more